Overview
- Kenvue investors will receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per share, valuing Kenvue at about $21.01 based on Friday’s close.
- Kimberly-Clark shareholders are expected to own roughly 54% of the combined company, with Kenvue holders at about 46%.
- The companies project roughly $32 billion in annual revenue and about $1.9–$2.1 billion in cost savings within three years after closing.
- Closing is targeted for the second half of 2026 subject to regulatory reviews and shareholder approvals, with CEO Mike Hsu set to lead from Irving, Texas.
- The agreement follows public claims challenging Tylenol’s safety and a new Texas lawsuit, as shares jumped roughly 17–20% for Kenvue and fell about 10–16% for Kimberly-Clark.